Common Side Effects Needing Monitoring
Cosentyx (secukinumab) commonly causes upper respiratory tract infections, diarrhea, and nasopharyngitis. Patients with a history of recurrent infections should use caution, as these can worsen existing conditions. Monitor for signs of infection and consider pausing treatment if severe.[1]
Infections: Key Precaution Area
Serious infections like tuberculosis, bacterial sepsis, invasive fungal infections, and viral infections occur more often with Cosentyx due to its IL-17A inhibition, which suppresses immune responses. Screen for latent TB before starting; avoid in active infections. Live vaccines are contraindicated.[1][2]
Inflammatory Bowel Disease Risks
New onset or worsening of Crohn's disease and ulcerative colitis have been reported. Patients with a history of IBD require close monitoring; discontinue if symptoms like severe abdominal pain or bloody stools emerge.[1]
Hypersensitivity Reactions
Serious allergic reactions, including anaphylaxis and angioedema, can happen during or after infusion/subcutaneous administration. Have emergency measures ready; stop treatment if severe reactions occur. Mild reactions like rash or urticaria may need dose adjustments.[1][2]
Increased Infection Risk in Specific Groups
Immunocompromised patients, those on concurrent immunosuppressants, or with chronic conditions like diabetes face higher infection risks. Use lowest effective dose and monitor closely. Avoid in patients with active malignancy due to potential immune suppression effects.[1]
Other Precautions for Vulnerable Patients
- Elderly: Higher infection rates; weigh benefits vs. risks.
- Pregnancy/Breastfeeding: Limited data; use only if benefits outweigh risks, as it crosses the placenta.
- Liver/Kidney Issues: No specific dose adjustments, but monitor for infections.
Neutropenia is rare but requires blood count checks if symptoms appear.[1][2]
Sources
[1]: Cosentyx Prescribing Information (Novartis)
[2]: FDA Label for Cosentyx